1. Home
  2. RYTM vs PIPR Comparison

RYTM vs PIPR Comparison

Compare RYTM & PIPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$85.67

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Logo Piper Sandler Companies

PIPR

Piper Sandler Companies

HOLD

Current Price

$84.04

Market Cap

5.8B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
RYTM
PIPR
Founded
2008
1895
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Bankers/Brokers/Service
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
5.8B
IPO Year
2017
2003

Fundamental Metrics

Financial Performance
Metric
RYTM
PIPR
Price
$85.67
$84.04
Analyst Decision
Strong Buy
Buy
Analyst Count
14
3
Target Price
$131.14
$91.38
AVG Volume (30 Days)
960.8K
460.5K
Earning Date
05-05-2026
05-01-2026
Dividend Yield
N/A
2.34%
EPS Growth
28.34
54.49
EPS
N/A
15.82
Revenue
N/A
$1,904,217,000.00
Revenue This Year
$54.90
$12.30
Revenue Next Year
$86.58
$13.55
P/E Ratio
N/A
$5.29
Revenue Growth
N/A
24.33
52 Week Low
$55.31
$72.48
52 Week High
$122.20
$380.26

Technical Indicators

Market Signals
Indicator
RYTM
PIPR
Relative Strength Index (RSI) 47.04 17.12
Support Level $84.39 $72.48
Resistance Level $93.51 $347.70
Average True Range (ATR) 4.21 2.84
MACD 0.73 2.29
Stochastic Oscillator 69.07 98.22

Price Performance

Historical Comparison
RYTM
PIPR

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

About PIPR Piper Sandler Companies

Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services followed by Equity financing.

Share on Social Networks: